MedPath

MaYingLong Pharmaceutical Group CO.,LTD.

🇨🇳China
Ownership
-
Established
1994-05-09
Employees
1.9K
Market Cap
-
Website
https://www.mayinglong.cn
Introduction

The company (600993.SH) was founded in 1582 AD and is a “time-honored Chinese brand” enterprise that has continued to operate for 440 years. Adhering to the development idea of “unifying target customers and diversifying service functions”, the company is committed to providing customers with specialized, personalized and diversified anorectal health solutions, vigorously developing the big health industry, and forming a group enterprise integrating the four major business segments of pharmaceutical industry, big health, medical services, and pharmaceutical business. The company focuses on the anorectal and lower digestive tract fields, creates a provider of anorectal health solutions, and vigorously develops the big health industry. Through the deepening implementation of the brand management strategy, the industrial chain was extended to the diagnosis and treatment industry according to the development idea of “unification of target customers and diversification of service functions”, Internet medical care was vigorously developed, and development opportunities were actively sought around the health sector, and the industrial layout of the pharmaceutical industry, medical services, and pharmaceutical business was formed. The company owns more than 10 exclusive drugs, such as Ma Yinglong Musk Hemorrhoid Cream, Musk Hemorrhoid Suppositories, Ma Yinglong Babao Eye Cream, and Dragon Ball Ointment. The company's qualifications and honors include the Order of the Chinese Red Cross Society, the China 500 Most Valuable Brand Certificate (22,857 billion yuan), the China 500 Most Valuable Brand Medal, private enterprises with outstanding contributions, and the Hubei Intelligent Manufacturing Demonstration Unit in 2017.6.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

113

NMPA:113

Drug Approvals

Balsalazide Sodium Capsules

Product Name
巴柳氮钠胶囊
Approval Number
国药准字H20194078
Approval Date
Sep 14, 2024
NMPA

Polyethylene Glycol Electrolytes Powder (III)

Product Name
复方聚乙二醇电解质散(Ⅲ)
Approval Number
国药准字H20243467
Approval Date
Apr 11, 2024
NMPA

益气通便颗粒

Approval Number
国药准字Z20090908
Approval Date
Feb 5, 2024
NMPA

Tofacitinib Citrate Tablets

Product Name
枸橼酸托法替布片
Approval Number
国药准字H20234416
Approval Date
Oct 27, 2023
NMPA

阳春口服液

Approval Number
国药准字Z20044082
Approval Date
Jan 17, 2023
NMPA

麦味地黄口服液

Approval Number
国药准字Z20044081
Approval Date
Jan 17, 2023
NMPA

Ciclopirox Olamine Vaginal supppositories

Product Name
环吡酮胺阴道栓
Approval Number
国药准字H20083338
Approval Date
Jan 17, 2023
NMPA

阳春玉液

Approval Number
国药准字Z20044083
Approval Date
Jan 17, 2023
NMPA

Macrogol 4000 Powder

Product Name
聚乙二醇4000散
Approval Number
国药准字H20080092
Approval Date
Sep 9, 2022
NMPA

Morphine Sulfate Suppositories

Product Name
硫酸吗啡栓
Approval Number
国药准字H20080147
Approval Date
Sep 9, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.